Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Docetaxel, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
This statement is based on a regulatory approval from the Health Canada:
PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.